Blood Cancer Journal (Dec 2022)
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
- Farhad Ravandi,
- Robert J. Kreitman,
- Enrico Tiacci,
- Leslie Andritsos,
- Versha Banerji,
- Jacqueline C. Barrientos,
- Seema A. Bhat,
- James S. Blachly,
- Alessandro Broccoli,
- Timothy Call,
- Dai Chihara,
- Claire Dearden,
- Judit Demeter,
- Sasha Dietrich,
- Monica Else,
- Narendranath Epperla,
- Brunangelo Falini,
- Francesco Forconi,
- Douglas E. Gladstone,
- Alessandro Gozzetti,
- Sunil Iyengar,
- James B. Johnston,
- Jeffrey Jorgensen,
- Gunnar Juliusson,
- Francesco Lauria,
- Gerard Lozanski,
- Sameer A. Parikh,
- Jae H. Park,
- Aaron Polliack,
- Graeme Quest,
- Tadeusz Robak,
- Kerry A. Rogers,
- Alan Saven,
- John F. Seymour,
- Tamar Tadmor,
- Martin S. Tallman,
- Constantine S. Tam,
- Philip A. Thompson,
- Xavier Troussard,
- Clive S. Zent,
- Thorsten Zenz,
- Pier Luigi Zinzani,
- Bernhard Wörmann,
- Kanti Rai,
- Michael Grever
Affiliations
- Farhad Ravandi
- Department of Leukemia, University of Texas MD Anderson Cancer Center
- Robert J. Kreitman
- Laboratory of Molecular Biology, National Cancer Institute, NIH
- Enrico Tiacci
- Institute of Hematology, Department of Medicine and Surgery, University and Hospital of Perugia
- Leslie Andritsos
- University of New Mexico Comprehensive Cancer Center
- Versha Banerji
- Department of Internal Medicine & Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba
- Jacqueline C. Barrientos
- Feinstein Institutes for Medical Research and Zucker School of Medicine at Hofstra/Northwell
- Seema A. Bhat
- Division of Hematology, Department of Internal Medicine, The Ohio State University
- James S. Blachly
- Division of Hematology, Department of Internal Medicine, The Ohio State University
- Alessandro Broccoli
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna
- Timothy Call
- Division of Hematology, Mayo Clinic
- Dai Chihara
- Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center
- Claire Dearden
- The Royal Marsden NHS Foundation Trust
- Judit Demeter
- Department of Internal Medicine and Oncology, Semmelweis University
- Sasha Dietrich
- Department of Hematology, University Hospital of Heidelberg
- Monica Else
- Division of Molecular Pathology, The Institute of Cancer Research
- Narendranath Epperla
- Division of Hematology, Department of Internal Medicine, The Ohio State University
- Brunangelo Falini
- Institute of Hematology, Department of Medicine and Surgery, University and Hospital of Perugia
- Francesco Forconi
- School of Cancer Sciences, Cancer Research UK Southampton Centre, Faculty of Medicine, University of Southampton
- Douglas E. Gladstone
- Johns Hopkins Kimmel Cancer Center Baltimore
- Alessandro Gozzetti
- Dept. of Medicine, Surgery and Neurosciences, University of Siena, Policlinico S. Maria alle Scotte-
- Sunil Iyengar
- The Royal Marsden NHS Foundation Trust
- James B. Johnston
- Department of Internal Medicine, University of Manitoba
- Jeffrey Jorgensen
- Department of Hematopathology, University of Texas MD Anderson Cancer Center
- Gunnar Juliusson
- Lund University Stem Cell Center
- Francesco Lauria
- University of Siena
- Gerard Lozanski
- Department of Pathology, The Ohio State University Medical Center
- Sameer A. Parikh
- Division of Hematology, Mayo Clinic
- Jae H. Park
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Aaron Polliack
- Hadassah University Hospital
- Graeme Quest
- Kingston Health Sciences Centre
- Tadeusz Robak
- Department of Hematology, Medical University of Lodz
- Kerry A. Rogers
- Division of Hematology, Department of Internal Medicine, The Ohio State University
- Alan Saven
- Division of Hematology and Oncology, Scripps Clinic
- John F. Seymour
- Haematology Department, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, University of Melbourne
- Tamar Tadmor
- Hematology Unit, Bnai Zion Medical Center; and the Ruth and Bruce Rappaport Faculty of Medicine, Technion
- Martin S. Tallman
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Constantine S. Tam
- Department of Haematology, Alfred Hospital and Monash University
- Philip A. Thompson
- Department of Leukemia, University of Texas MD Anderson Cancer Center
- Xavier Troussard
- Department of Hematology, Centre Hospitalier Universitaire Cote de Nacre
- Clive S. Zent
- James P. Wilmot Cancer Institute, University of Rochester Medical Center
- Thorsten Zenz
- Dept. of Medical Oncology and Haematology, University Hospital Zürich and University of Zurich (UZH)
- Pier Luigi Zinzani
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna
- Bernhard Wörmann
- The Charité – Universitätsmedizin Berlin
- Kanti Rai
- Feinstein Institutes for Medical Research and Zucker School of Medicine at Hofstra/Northwell
- Michael Grever
- Division of Hematology, Department of Internal Medicine, The Ohio State University
- DOI
- https://doi.org/10.1038/s41408-022-00760-z
- Journal volume & issue
-
Vol. 12,
no. 12
pp. 1 – 7
Abstract
Abstract A significant body of literature has been generated related to the detection of measurable residual disease (MRD) at the time of achieving complete remission (CR) in patients with hairy cell leukemia (HCL). However, due to the indolent nature of the disease as well as reports suggesting long-term survival in patients treated with a single course of a nucleoside analog albeit without evidence of cure, the merits of detection of MRD and attempts to eradicate it have been debated. Studies utilizing novel strategies in the relapse setting have demonstrated the utility of achieving CR with undetectable MRD (uMRD) in prolonging the duration of remission. Several assays including immunohistochemical analysis of bone marrow specimens, multi-parameter flow cytometry and molecular assays to detect the mutant BRAF V600E gene or the consensus primer for the immunoglobulin heavy chain gene (IGH) rearrangement have been utilized with few comparative studies. Here we provide a consensus report on the available data, the potential merits of MRD assessment in the front-line and relapse settings and recommendations on future role of MRD assessment in HCL.
